Norstella

Norstella does not publicly disclose its ownership structure. The firm formed through the 2021 merger of MMIT and Evaluate, backed by private equity, but the specific sponsor or family office behind it is not named (per Norstella website).

Norstella's five core brands are Evaluate (pharma intelligence), MMIT (market access data), Citeline (trial intelligence), Panalgo (real-world analytics), and Entact (payer data assets). These brands collectively cover the drug development life cycle from pipeline to patient.

Norstella sells data, analytics, and AI-driven software tools to pharmaceutical, medtech, and clinical research organizations. Its products cover forecasting, trial design, market access, and patient activation, and it competes with firms like IQVIA.

No public evidence suggests Norstella makes equity investments in external companies or funds. Its business is providing data and analytics services, not deploying capital as an asset manager.

LinQ is Norstella's AI engine that integrates data from its five brands into a single asset, enabling faster decisions across forecasting, trial design, market access, and patient activation. Norstella describes it as the biopharma industry's first fully integrated data asset.

Norstella does not publicly disclose its total headcount or the number of investment professionals. The firm lists offices in 10 cities globally but provides no team size data on its website.

Norstella actively embeds AI across its product suite, including a proprietary AI engine that drives its LinQ platform. The firm publishes white papers and ebooks on AI in drug development and claims to be ranked 4th most innovative data science company in 2025 (per Norstella).